Midesteine is a synthetic compound that has been studied for its potential therapeutic effects. It is a derivative of N-acetylcysteine (NAC), a well-known antioxidant and mucolytic agent. Midesteine has shown promising results in preclinical studies for its ability to protect against oxidative stress, inflammation, and apoptosis. It has also been investigated for its potential to improve cognitive function and memory. The compound's mechanism of action is thought to involve its ability to enhance the activity of the antioxidant enzyme glutathione peroxidase. Midesteine has been studied for its potential use in the treatment of various conditions, including neurodegenerative diseases, cardiovascular disease, and respiratory disorders. Further research is ongoing to evaluate its clinical efficacy and safety.'
midesteine: a cyclic thiolic neutrophil elastase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 65837 |
| CHEMBL ID | 1808549 |
| SCHEMBL ID | 724755 |
| MeSH ID | M0171887 |
| Synonym |
|---|
| mr-889 |
| midesteine |
| 2-thiophenecarbothioic acid, s-(1-methyl-2-oxo-2-((tetrahydro-2-oxo-3-thienyl)amino)ethyl) ester |
| midesteinum [inn-latin] |
| 2-thiophenecarbothioic acid, s-ester with (+-)-2-mercapto-n-(tetrahydro-2-oxo-3-thienyl)propionamide |
| mr 889 |
| 2-(thiophen-2-ylcarbonylthio)-n-(2-oxo-2,3,4,5-tetrahydrothiophen-3-yl)propionamide |
| midesteine [inn] |
| midesteina [inn-spanish] |
| s-[1-oxo-1-[(2-oxothiolan-3-yl)amino]propan-2-yl] thiophene-2-carbothioate |
| CHEMBL1808549 , |
| midesteinum |
| 90k2ye9fto , |
| unii-90k2ye9fto |
| midesteina |
| 94149-41-4 |
| bdbm50349435 |
| SCHEMBL724755 |
| 2-thiophenecarbothioic acid, s-ester with (+/-)-2-mercapto-n-(tetrahydro-2-oxo-3-thienyl)propionamide |
| n-(2-oxo-2,3,4,5-tetrahydro-3-thienyl)-2-(2-thienylcarbonylthio)propionamide |
| SB19618 |
| Q27271333 |
| DTXSID00869194 |
| s-{1-oxo-1-[(2-oxothiolan-3-yl)amino]propan-2-yl} thiophene-2-carbothioate |
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Neutrophil elastase | Homo sapiens (human) | IC50 (µMol) | 1.0000 | 0.0063 | 2.0734 | 22.3780 | AID609337 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| protease binding | Neutrophil elastase | Homo sapiens (human) |
| transcription corepressor activity | Neutrophil elastase | Homo sapiens (human) |
| endopeptidase activity | Neutrophil elastase | Homo sapiens (human) |
| serine-type endopeptidase activity | Neutrophil elastase | Homo sapiens (human) |
| protein binding | Neutrophil elastase | Homo sapiens (human) |
| heparin binding | Neutrophil elastase | Homo sapiens (human) |
| peptidase activity | Neutrophil elastase | Homo sapiens (human) |
| cytokine binding | Neutrophil elastase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| extracellular region | Neutrophil elastase | Homo sapiens (human) |
| extracellular space | Neutrophil elastase | Homo sapiens (human) |
| cytoplasm | Neutrophil elastase | Homo sapiens (human) |
| cytosol | Neutrophil elastase | Homo sapiens (human) |
| cell surface | Neutrophil elastase | Homo sapiens (human) |
| secretory granule | Neutrophil elastase | Homo sapiens (human) |
| azurophil granule lumen | Neutrophil elastase | Homo sapiens (human) |
| specific granule lumen | Neutrophil elastase | Homo sapiens (human) |
| phagocytic vesicle | Neutrophil elastase | Homo sapiens (human) |
| collagen-containing extracellular matrix | Neutrophil elastase | Homo sapiens (human) |
| extracellular exosome | Neutrophil elastase | Homo sapiens (human) |
| transcription repressor complex | Neutrophil elastase | Homo sapiens (human) |
| extracellular space | Neutrophil elastase | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID609337 | Inhibition of human neutrophil elastase using N-methylsuccinyl-Ala-Ala-Pro-Val-7-amino-4-methyl-coumarin as substrate measured every 30 secs for 10 mins by fluorescence microplate reader | 2011 | Bioorganic & medicinal chemistry, Aug-01, Volume: 19, Issue:15 | Design, synthesis and evaluation of N-benzoylindazole derivatives and analogues as inhibitors of human neutrophil elastase. |
| AID1248074 | Inhibition of neutrophil elastase in human whole blood using MeO-Succ-Ala-Ala-Pro-Val-pNA as substrate after 30 mins by colorimetric analysis | 2015 | Bioorganic & medicinal chemistry letters, Oct-15, Volume: 25, Issue:20 | Neutrophil elastase inhibitors for the treatment of (cardio)pulmonary diseases: Into clinical testing with pre-adaptive pharmacophores. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.62) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (12.50%) | 5.53% |
| Reviews | 1 (12.50%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (75.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||